‘It’s a Time of Hope’ for Kidney Cancer


With new treatments being explored, it’s an exciting time for patients with kidney cancer, an expert explained.

Recent years have brought new therapies for patients with kidney cancer, and with even more advancements on the horizon, “it’s a time of hope for patients,” explained Dr. Toni Choueiri.

In an interview at the 2023 Kidney Cancer Research Summit (KCRS), Choueiri, director of the Lank Center for Genitourinary Oncology, medical director of International Strategic Initiatives at the Dana-Farber Cancer Institute and Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School, recently discussed the exciting new updates for patients with renal cell carcinoma (RCC).

Choueiri mentioned the advent of PD-1, VEGF and CTLA3 inhibitors — types drugs that block proteins that aid in the survival of cancer cells — continues to evolve, while new drugs and combinations continue to be explored.

“So I think this is a great time for investigators in kidney cancer, it's a time of hope for patients, there is no doubt it's a time of hope for patients,” Choueiri said.


You know, I think if you go five years before the PD-1, VEGF, that in combination, CTLA3 are important. It's becoming, you know, I wouldn't say mundane, but it's evolving. But actually, new targets are exciting. If two inhibitors are coming, we're planning a lot of studies, not just with (Welireg [belzutifan]), which is ahead, but certainly with other drugs. We're seeing CAR-T cells and cellular therapy and TILs in … renal cell cancer. There is, as I was saying, and emergence of antibody drug conjugates, and there is a deep knowledge that is evolving by the day about the biology of clear cell RCC as well as multiple variant histologies (that) are seen.

(There is) no doubt in my mind (that this) can lead to trials, and then we have to see what they show. I mean, it's so beautiful (to see) data about translocation chromophobe in renal cell cancer. So I think this is a great time for investigators in kidney cancer, it's a time of hope for patients, there is no doubt it's a time of hope for patients.

If you look at metastatic RCC patient survival, it's over five years now, and hopefully more to come. We can’t stop yet and important meetings like this like a KCRS meeting with KidneyCan are going to lead us to more collaboration, and more hope to cure this disease.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Woman with dark brown hair and pink lipstick wearing a light pink blouse with a light brown blazer. Patients should have conversations with their providers about treatments after receiving diagnoses.
Man in a navy suit with a purple tie. Dr. Saby George talks to CURE about how treatment with Opdivo could mitigate disparities in patients with kidney cancer.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE